Cetrotide / Cetrorelix acetate
Active ingredient: 0.25 mg of cetrorelix (as cetrorelix acetate)
Medicinal Product: Powder and solvent for solution for injection.
Pharmacotherapeutic group. Anti-gonadotropin releasing hormones.
ATС code H01C C02.
Registration Certificate No. UA / 4898/01/01
Prevention of premature ovulation in patients through controlled ovarian stimulation followed by oocyte extraction and the use of auxiliary reproductive technologies.
Hypersensitivity to the active substance or to any structural analogues of the gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or auxiliary substances of the preparation; pregnancy and breastfeeding period; postmenopausal period; moderate or severe damage to the renal or hepatic functions.
Method of administration and dose.
If the doctor did not prescribe a different dosing regimen, then the recommendations below should be followed.
The contents of one vial (0.25 mg of cetrorelix) are administered once daily with 24-hour intervals either in the morning or in the evening.
Introduction of the drug in the morning: administration of Cetrotide ® 0.25 mg starts on the 5th or 6th day of the cycle of ovarian stimulation (approximately 96-120 hours after the start of ovarian stimulation with the use of urinary or recombinant gonadotrophin preparations) and continues during the period of use of gonadotropins, including the day of induction of ovulation or the day of administration of human chorionic gonadotrophin (hCG).
Administration of the drug in the evening: administration of Cetrotide® 0.25 mg starts on the 5th day of the cycle of ovarian stimulation (approximately 96 to 108 hours after the start of ovarian stimulation with the use of urinary or recombinant gonadotrophin preparations) and continues during the period of gonadotrophin use until the evening before the day induction of ovulation inclusive.
From the immune system: uncommon – systemic allergic/pseudo-allergic reactions, including life-threatening anaphylactic reactions.
On the nervous system: uncommon – headache.
From the digestive tract: not common – nausea.
From the reproductive system and mammary glands: widespread – a syndrome of hyperstimulation of the ovaries from mild to moderate severity, which is an inherent risk of stimulation; Uncommon – severe syndrome of ovarian hyperstimulation.
General disorders and administration site reactions: Common – local reactions at the injection site (such as erythema, edema or itching). They are usually temporary and light on severity.